Načítá se...
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy
AIM(S): Insulin-like growth factor-1 receptor (IGF-1R) targeted therapies have become one of the intriguing areas in anticancer drug development during the last decade. As one of these therapies, anti-IGF-1R monoclonal antibodies (mAbs) are also advancing further in development. Our purpose was to c...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Science Inc
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4093917/ https://ncbi.nlm.nih.gov/pubmed/24033707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12228 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|